RNA Vaccine for Herpes Simplex Virus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA vaccination techniques for herpes simplex virus (HSV) pose risks such as insertional mutagenesis and may trigger unwanted cellular responses, and they are less effective in producing balanced immune responses compared to RNA-based approaches.
Innovation Solution
Development of RNA vaccines that utilize modified RNA (mRNA) to direct the body's cellular machinery to produce specific HSV antigens, inducing both cellular and humoral immunity without the risks associated with DNA vaccination, and are formulated with components like aluminum hydroxide and 3-O-deacylated monophosphoryl lipid A for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA vaccination is used to stimulate immune response to HSV antigens, then immune response is produced, but risk of insertional mutagenesis and unwanted cellular responses increases
Solution Approach 1:
The patent extracts the harmful DNA component from the vaccination system and replaces it with RNA. The RNA vaccine delivers the antigen-encoding sequence without integrating into the host genome, thereby eliminating the risk of insertional mutagenesis while still producing the desired immune response.
Solution Approach 2:
The patent changes the molecular parameter of the nucleic acid from DNA to RNA. This fundamental parameter change alters the biological behavior: RNA remains in the cytoplasm for translation without integrating into genomic DNA, thus preventing mutagenesis while maintaining antigen production capability.
2Reliability
If DNA vaccination is used to produce immune response, then antigen production occurs, but balanced immune response (cellular and humoral) is less effective
Solution Approach 1:
The patent changes the nucleic acid type from DNA to RNA, which fundamentally alters the immune response profile. RNA vaccines naturally elicit both strong cellular (CD8+ T cell) and humoral (antibody) responses, achieving a more balanced immune response with higher antibody titers and faster response times compared to DNA vaccines.
Data Source
AI summary
Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.